tri semaglutide Retatrutide vs and Tirzepatide: GLP-3 Facts explained retatrutide semaglutide vs. Ozempic: The

doi: 10.3389/fphar.2025.1704083 Received 12 September 2025 Revised 16 December 2025 Accepted 18 December 2025 Published 21 January 2026 Volume 16 - 2025 Edited by Chen Ling, Fudan University, China Reviewed by Wentao Jia, Changhai Hospital, China Jie Cheng, Jiangsu University of Science and Technology, China Updates Copyright 2026 Li, Zhang, Li and Zheng

[1] The FDA label for tirzepatide includes warnings about acute gallbladder disease, as GLP-1 receptor agonists have been associated with an increased risk of cholelithiasis or cholecystitis

DPCs were further purified and extracted using a cloning loop

Four out of nine does aborted at the highest dose level, and body weight was reduced in this group

Access the CareFirst Mobile App for on-the-go resources and account information